Accueil   Diary - News   All news Alizé Pharma reports positive results

Alizé Pharma reports positive results

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of a Phase Ib trial for AZP-531 in 36 Type 2 Diabetes (T2D) patients. This trial was the last stage in an overall Phase I program performed in 112 healthy volunteers, obese subjects and T2D patients.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree